evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3 questions · 3 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Summary of findings: tobramycin for inhalation powder vs tobramycin

Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).

1 finding from 1 review